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Bu with 2 nucleoside analogs ban be utilized to improve currently
available treatment programs for advanced myeloid leukemias.263
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T-cell depleted allogeneic hematopoietic stem cell transplants
(TCD-HSCT) have demonstrated durable disease free survival
with a low risk of graft vs. host disease (GVHD) in patients with
AML, MDS and NHL.We investigated this approach in 60 consec-
utive adult patients with ALL who underwent TCD-HSCT from
May 1997 through December 2008. Patients received myeloablative
cytoreduction consisting of hyperfractionated total body irradiation
(1375-1500cGy), followed by thiotepa (10mg/kg) and either cyclo-
phosphamide (120mg/kg, n 5 22) or fludarabine (125mg/m2, n 5
38). No immunosuppressive agents were used post-HSCT. There
were 39 males and 21 females. The median age was 36 years (range,
18-63). Twenty-seven patients were in hematologic CR1, 18 in CR2,
11 in CR3 or greater, and 4 patients had relapsed or refractory dis-
ease. Baseline cytogenetics were classified as poor risk (n 5 26, in-
cluding Ph1 5 17), standard risk (n 5 26), good risk (n 5 4) or
non-evaluable (n 5 4). Forty-eight patients had a B-cell and 10
a T cell phenotype (multilineage 5 1, unknown 5 1). Bone marrow
grafts were depleted of T-cells by soybean lectin agglutination and
sheep erythrocyte rosette depletion and PBSC grafts underwent
CD341 positive selection using the ISOLEX 300i Magnetic Cell
Separator and sheep erythrocyte rosette depletion. Twenty-four pa-
tients received grafts from HLA matched related donors (MRD), 8
from a single allele disparate related donor (MMRD), 15 from
HLAmatched unrelated donors (MUD), 13 fromHLAmismatched
unrelated donors (MMUD).With a median follow-up of 8.4 months
(range 0.2-149 months), 5-year overall survival (OS) and progres-
sion-free-survival (PFS) were 45% and 30%, respectively. The re-
lapse rate was 30% in patients in CR at time of HSCT. The 4
patients with relapsed or refractory disease died of relapse (n 5 3)
or infection (n 5 1). Ten of 58 evaluable patients (17%) developed
grade 2-3 aGVHD post-HSCT (MRD 5 2, MUD 5 3, MMRD
5 4, MMUD 5 1); cGVHD occurred in 13% evaluable patients.
We examined factors that predict outcomes in patients with ALL,
and we found that only disease status at time of HSCT predicted
PFS (p \ 0.001). Pre-HSCT LDH was predictive of OS (p 5
0.047). No effect was observed for cytogenetics, WBC at diagnosis,
or presence of extramedullary disease. While TCD-HSCT does
provide acceptable OS and PFS without GVHD in adult patients
with ALL, relapse remains a limiting factor. Future studies focusing
on novel conditioning regimens and/or maintenance therapy are
warranted.264
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Introduction: Leukemic relapse following initial induction chemo-
therapy has been predicted independently by the rate of peripheral
blast clearance in adult AML and pediatric ALL. This early response
to therapy in de-novo acute leukemia may indicate in-vivo chemo-
sensitivity of malignant cells. No reports exist on whether blastresponse is predictive of relapse after myeloablative conditioning
for allogeneic hematopoietic stem cell transplantation (AlloHSCT).
Methods:We analyzed 69 patients with AML (n 5 47), MDS (n 5
17), and ALL (n5 5) who had circulating blasts prior to busulfan- or
TBI-based myeloablative AlloHSCT at a single academic center
from 1998 to 2009. Individual regression slopes for consecutive
values of circulating blasts were calculated throughout conditioning
chemotherapy. Relapse-free (RFS) and overall survival (OS) were es-
timated by Kaplan-Meier method and Cox proportional hazards
model.
Results: The median age of patients (49% males) was 47 years
(range, 20-62). 31 (45%) receivedmore than one prior chemotherapy
regimen; 31 (45%) had unrelated donor AlloHSCT; 14 (20%) re-
ceived TBI-based preparation; 34 (49%) relapsed after AlloHSCT.
50 (73%) patients were able to clear their circulating blasts within
median of 6.5 days (range, 2-10). Time to blast clearance was associ-
atedwith underlyingmalignancy (median of 4, 7, and 8 days for ALL,
MDS, and AML respectively, p\ 0.001) and myeloablative condi-
tioning (median of 4 days for TBI- vs. 8 days for busulfan-based
preparation, p \ 0.001). Median average slope of blast clearance
was -15.9 per day (range, -65.2 to 10.3). Neither velocity of blast de-
cline (p5 0.4) nor the number of days to circulating blast clearance (p
5 0.35) was predictive for time to disease relapse.More than one pre-
vious chemotherapy was associated with higher relapse rate (hazard
ratio [HR]5 2.5, p\0.01) andworseOS (HR5 2.2, p\0.01), while
receiving TBI-containing preparation portended poor OS (HR 5
2.3, p\ 0.01) in multivariable analysis.
Conclusions: The number of previous chemotherapies, but not the
slope of circulating blast decline during myeloablative conditioning
for AlloHSCT, predicted disease relapse and OS in patients with cir-
culating blasts.265
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Patients with CBF-AML are regarded as having a favorable out-
come when treated with anthracycline-based induction chemother-
apy and multiple cycles of high-dose cytarabine consolidation.
Most data indicating the favorable prognosis of CBF-AML with
non-HSCT management originates from young selected patients
participating in clinical trials with scarce information on salvage
treatment. We performed a retrospective analysis of 30 consecutive
patients diagnosed with CBF-AML (14 with t(8;21) and 16 with inv
(16)) at a regional leukemia center over twelve years to assess long
term survival and the likelihood of therapeutic success without
ever requiring HSCT. We reviewed the charts of all patients with
CBF-AML (irrespective of other cytogenetic abnormalities) to ex-
tract demographic, treatment, and outcome information. Survival
status and subsequent treatments in other institutions were deter-
mined by contacting the patient, attending physician or review of
public death records. All patients were treated with curative intent
with anthracycline-based induction therapy, and 47% were on clin-
ical trials. Median age at diagnosis was 43 years (range 18-69). There
was 1 death during induction therapy and 22/29 patients (73.3%)
achieved a complete remission with initial induction therapy. Me-
dian follow up for survivors was 35.3 months (range 6.4-117.4)
with all survivors currently in remission. Overall 13 patients
(43.3%) have required some modality of HSCT. Six patients re-
ceived HSCT in CR1 due to perceived high risk of relapse (5 autol-
ogous, 1 allogeneic), none of which have relapsed. Among the 16
patients receiving non-transplant consolidation in CR1, 6 have sub-
sequently relapsed and required aHSCT (3 autologous, 3 allogeneic)
and 3 of these patients are alive 20.9-117.4 months from the initial
diagnosis. Seven patients received HSCT in CR2 or in relapse (4 au-
tologous, 3 allogeneic) and 6 of these patients are long-term survi-
vors. Estimated 5 year overall survival for the entire cohort is 58.8
1/- 10.8%, comparable to what has been described for younger pa-
tients entering clinical trials (Grimwade et al, 2010). The likelihood
